NO2007016I2 - Nelarabin eller et farmasoytisk akseptabelt salt derav ( nelarabin=9-(beta-D-arabinofuranosyl-2-amino-6-metoksy-9H-purin) - Google Patents

Nelarabin eller et farmasoytisk akseptabelt salt derav ( nelarabin=9-(beta-D-arabinofuranosyl-2-amino-6-metoksy-9H-purin)

Info

Publication number
NO2007016I2
NO2007016I2 NO2007016C NO2007016C NO2007016I2 NO 2007016 I2 NO2007016 I2 NO 2007016I2 NO 2007016 C NO2007016 C NO 2007016C NO 2007016 C NO2007016 C NO 2007016C NO 2007016 I2 NO2007016 I2 NO 2007016I2
Authority
NO
Norway
Prior art keywords
nelarabine
pharmaceutically acceptable
arabinofuranosyl
purine
methoxy
Prior art date
Application number
NO2007016C
Other languages
English (en)
Other versions
NO2007016I1 (no
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of NO2007016I1 publication Critical patent/NO2007016I1/no
Publication of NO2007016I2 publication Critical patent/NO2007016I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NO2007016C 1987-05-30 2007-12-21 Nelarabin eller et farmasoytisk akseptabelt salt derav ( nelarabin=9-(beta-D-arabinofuranosyl-2-amino-6-metoksy-9H-purin) NO2007016I2 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712745A GB8712745D0 (en) 1987-05-30 1987-05-30 Antiviral compounds

Publications (2)

Publication Number Publication Date
NO2007016I1 NO2007016I1 (no) 2008-01-14
NO2007016I2 true NO2007016I2 (no) 2008-06-23

Family

ID=10618179

Family Applications (2)

Application Number Title Priority Date Filing Date
NO882357A NO172543C (no) 1987-05-30 1988-05-27 Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte purinarabinosider
NO2007016C NO2007016I2 (no) 1987-05-30 2007-12-21 Nelarabin eller et farmasoytisk akseptabelt salt derav ( nelarabin=9-(beta-D-arabinofuranosyl-2-amino-6-metoksy-9H-purin)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO882357A NO172543C (no) 1987-05-30 1988-05-27 Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte purinarabinosider

Country Status (31)

Country Link
US (2) US5424295A (no)
EP (1) EP0294114B1 (no)
JP (1) JP2667873B2 (no)
KR (1) KR970009474B1 (no)
CN (1) CN1020107C (no)
AT (1) ATE142636T1 (no)
AU (1) AU622403B2 (no)
CA (1) CA1330990C (no)
CS (1) CS277006B6 (no)
CY (2) CY2001A (no)
DD (2) DD282694A5 (no)
DE (2) DE3855522T2 (no)
DK (1) DK171670B1 (no)
ES (1) ES2091750T3 (no)
FI (1) FI89805C (no)
GB (1) GB8712745D0 (no)
GR (1) GR3021257T3 (no)
HK (1) HK78497A (no)
HU (2) HU205001B (no)
IL (1) IL86531A (no)
LU (1) LU91370I2 (no)
MC (1) MC1935A1 (no)
MY (1) MY103567A (no)
NL (1) NL300302I2 (no)
NO (2) NO172543C (no)
NZ (1) NZ224813A (no)
PH (1) PH27292A (no)
PL (1) PL157684B1 (no)
PT (1) PT87592B (no)
SA (1) SA99200688A (no)
ZA (2) ZA883829B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8712745D0 (en) * 1987-05-30 1987-07-01 Wellcome Found Antiviral compounds
US7307166B1 (en) * 1987-10-28 2007-12-11 Wellstat Therapeutics Corporation Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
KR910007655A (ko) * 1989-10-03 1991-05-30 엠. 피. 잭슨 치료용 뉴클레오시드
US5206351A (en) * 1990-06-15 1993-04-27 Ash Stevens, Inc. Process for the preparation of 2-amino (2,3,5-tri-o-benzyl-beta-d-arabinofuranosyl)adenine
GB9015914D0 (en) * 1990-07-19 1990-09-05 Wellcome Found Heterocyclic compounds
US5283331A (en) * 1990-12-20 1994-02-01 Nippon Kayaku Kabushiki Kaisha 2-halogeno-oxetanocin A and phosphoric ester thereof
GB9104165D0 (en) * 1991-02-27 1991-04-17 Wellcome Found Novel entities for hiv therapy
US5961987A (en) * 1996-10-31 1999-10-05 University Of Iowa Research Foundation Ocular protein stimulants
JP3619017B2 (ja) 1998-06-24 2005-02-09 日本臓器製薬株式会社 新規アラビノシルアデニン誘導体
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
JP4555536B2 (ja) * 2000-02-18 2010-10-06 サザン・リサーチ・インスティテュート ２−クロロ−９−（２−デオキシ−２−フルオロ−β−Ｄ−アラビノフラノシル）−９Ｈ−プリン−６−アミンの合成方法
US6753322B2 (en) * 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
JP3421330B2 (ja) * 2000-11-02 2003-06-30 持田製薬株式会社 ビダラビン注射用乾燥製剤
US7321033B2 (en) * 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
DE60234376D1 (de) * 2001-11-27 2009-12-24 Anadys Pharmaceuticals Inc 3-beta-d-ribofuranosylthiazolo(4,5-delta)pyridimin-nucleoside und ihre verwendung
KR20050059199A (ko) * 2002-09-30 2005-06-17 제네랩스 테크놀로지스, 인코포레이티드 Ｃ형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
TWI407956B (zh) * 2004-12-17 2013-09-11 Anadys Pharmaceuticals Inc ３，５-二取代和３，５，７-三取代-３Ｈ-唑并及３Ｈ-噻唑并〔４，５-ｄ〕嘧啶-２-酮化合物及其前藥
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
EP1973920B1 (en) 2005-11-21 2010-07-21 Anadys Pharmaceuticals, Inc. Process for the preparation of 5-amino-3h-thiazolo [4,5-d] pyrimidin-2-one
ATE496924T1 (de) * 2006-06-22 2011-02-15 Anadys Pharmaceuticals Inc Prodrugs von 5-amino-3-(3'-deoxy-beta-d- ribofuranosyl)-thiazolä4,5-düpyrimidin-2,7-dion
DE602007012881D1 (en) 2006-07-18 2011-04-14 Anadys Pharmaceuticals Inc Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen
CN101092441A (zh) * 2007-07-17 2007-12-26 北京本草天源药物研究院 一种奈拉滨的合成方法
US7846912B2 (en) * 2007-09-13 2010-12-07 Protia, Llc Deuterium-enriched nelarabine
CN101768197A (zh) * 2008-12-29 2010-07-07 北京德众万全药物技术开发有限公司 一种奈拉滨的制备方法
CN103665076B (zh) * 2012-08-30 2018-01-09 上海阳帆医药科技有限公司 奈拉滨的制备方法
CN104892709B (zh) * 2015-06-04 2018-01-19 新乡学院 一种合成奈拉滨的方法
WO2018133835A1 (en) * 2017-01-20 2018-07-26 National Institute Of Biological Sciences, Beijing Nucleoside analogue regulating mammalian circadian rhythm
WO2022258014A1 (zh) * 2021-06-09 2022-12-15 正大天晴药业集团股份有限公司 用于制备奈拉滨的重组基因工程菌及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759011A (fr) * 1969-11-17 1971-05-17 Wellcome Found Aminopurines
US3758684A (en) * 1971-09-07 1973-09-11 Burroughs Wellcome Co Treating dna virus infections with amino purine derivatives
US4055718A (en) * 1976-05-17 1977-10-25 Parke, Davis & Company 9-(2-O-Acyl-β-D-arabinofuranosyl)-adenine compounds and method for their production
US4055717A (en) * 1976-05-17 1977-10-25 Parke, Davis & Company 9-(3-O-Acyl-β-D-arabinofuranosyl)adenine compounds, 9-(2,3-di-O-acyl-β-D-arabinofuranosyl)-adenine compounds, and method for their production
US4048432A (en) * 1976-05-17 1977-09-13 Parke, Davis & Company 9-(3,5-Di-O-acyl-β-D-arabinofuranosyl)adenine compounds and method for their production
JPS5515716A (en) * 1978-07-18 1980-02-04 Ajinomoto Co Inc Production of purine arabinoside
JPS6053941B2 (ja) * 1977-08-10 1985-11-28 日本電気株式会社 バイアスライト駆動方式
US4371613A (en) * 1977-08-10 1983-02-01 Ajinomoto Company Incorporated Method for producing purine arabinosides
GB1573777A (en) * 1977-11-03 1980-08-28 Wellcome Found 9-d-arabinonucleosides and an enzymatic process for their preparation
US4495180A (en) * 1982-06-21 1985-01-22 Merck & Co., Inc. Prodrugs of Ara-A an antiviral agent
JPS58225097A (ja) * 1982-06-23 1983-12-27 Yamasa Shoyu Co Ltd ヌクレオシド５′−アルキルもしくはアルケニルりん酸
IE73219B1 (en) * 1985-03-16 1997-05-07 Wellcome Found Therapeutic nucleosides
GB8712745D0 (en) * 1987-05-30 1987-07-01 Wellcome Found Antiviral compounds

Also Published As

Publication number Publication date
US5424295A (en) 1995-06-13
CY2008001I2 (el) 2009-11-04
LU91370I2 (fr) 2007-12-10
GR3021257T3 (en) 1997-01-31
DK289788D0 (da) 1988-05-27
ATE142636T1 (de) 1996-09-15
ZA897598B (en) 1990-01-31
NL300302I1 (nl) 2008-01-02
CY2008001I1 (el) 2009-11-04
PL272729A1 (en) 1989-02-06
HK78497A (en) 1997-06-20
DE122008000003I2 (de) 2010-02-04
MY103567A (en) 1993-08-28
FI882511A0 (fi) 1988-05-27
PT87592A (pt) 1989-05-31
NO2007016I1 (no) 2008-01-14
DE122008000003I1 (de) 2008-04-17
SA99200688A (ar) 2005-12-03
CS8803635A2 (en) 1990-09-12
DD282694A5 (de) 1990-09-19
NO172543B (no) 1993-04-26
PH27292A (en) 1993-05-04
PL157684B1 (pl) 1992-06-30
ES2091750T3 (es) 1996-11-16
GB8712745D0 (en) 1987-07-01
NO882357L (no) 1988-12-01
ZA883829B (en) 1990-01-31
DE3855522D1 (de) 1996-10-17
MC1935A1 (fr) 1989-05-19
IL86531A (en) 1993-07-08
EP0294114B1 (en) 1996-09-11
HU205001B (en) 1992-03-30
NO882357D0 (no) 1988-05-27
DK171670B1 (da) 1997-03-10
CA1330990C (en) 1994-07-26
KR880013967A (ko) 1988-12-22
EP0294114A2 (en) 1988-12-07
JPS63310831A (ja) 1988-12-19
DE3855522T2 (de) 1997-02-06
US5539098A (en) 1996-07-23
CN1020107C (zh) 1993-03-17
CN1031233A (zh) 1989-02-22
FI89805C (fi) 1993-11-25
HU895829D0 (en) 1990-01-28
JP2667873B2 (ja) 1997-10-27
HUT47129A (en) 1989-01-30
IL86531A0 (en) 1988-11-15
AU622403B2 (en) 1992-04-09
FI89805B (fi) 1993-08-13
NO172543C (no) 1993-08-04
NZ224813A (en) 1991-04-26
DK289788A (da) 1988-12-01
PT87592B (pt) 1992-09-30
CS277006B6 (en) 1992-11-18
EP0294114A3 (en) 1990-01-24
KR970009474B1 (ko) 1997-06-13
FI882511A (fi) 1988-12-01
CY2001A (en) 1997-12-05
HU199870B (en) 1990-03-28
NL300302I2 (nl) 2008-05-01
DD293962A5 (de) 1991-09-19
AU1671888A (en) 1988-12-01

Similar Documents

Publication Publication Date Title
NO2007016I2 (no) Nelarabin eller et farmasoytisk akseptabelt salt derav ( nelarabin=9-(beta-D-arabinofuranosyl-2-amino-6-metoksy-9H-purin)
MY103760A (en) Therapeutic nucleosides
ATE123285T1 (de) Antivirale pyrimidin- und purinverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate.
ATE63747T1 (de) Antivirale verbindungen.